Some selected highlights of Bamburgh Capital’s more recent experience are as follows:

Orbit is a financial services business focused on providing debt collection and account management to customers operating in the UK Water Industry.   We advised the owners of Orbit, providing strategic and operational support leading to a sale of the business to Cabot Credit Management for an undisclosed figure.   Bamburgh Capital ran a targeted, competitive sale process, helped structure and negotiate a deal and oversaw the due diligence and agreement of a sale & purchase agreement.

Ramsdens plc is a UK diversified financial business with one of the most respected management teams in its sector. Services include pawnbroking and foreign currency and the group has significant organic and acquisitive growth opportunities.  Bamburgh Capital advised the owners of the business, NorthEdge LLP and Ramsdens management, on the IPO, resulting in the successful admission to AIM raising £15m of capital, £5m of which was new money to fund growth.  The shares are up significantly since the AIM listing in Q1’2017.   Work undertaken by Bamburgh Capital included financial modelling, preparation and rehearsal of the investor presentation, test-marketing meetings and follow up meetings with blue chip institutional investors in London and Edinburgh, advice on selection of the corporate broker and other advisers and on the pricing and structuring of the IPO.

Collagen Solutions plc is an AIM listed specialist medical company that provides end-to-end collagen and biomaterial solutions to the biotech and pharmaceutical industry. Bamburgh Capital assisted former CEO Stewart White to create Collbio Limited in 2013, firstly acquiring specialist collagen manufacturing assets in Glasgow. This was followed later that year by a private fund raising, the acquisition of California based Collagen Solutions, and then an AIM listing. In 2014 we provided M&A advice on the acquisition of New Zealand based Southern Lights Biomaterials. Certain shareholders of Bamburgh Capital retain an equity shareholding in Collagen.

Peakdale Molecular is a leading UK-based provider of drug discovery services to the pharmaceutical, biotech, diagnostics and materials sciences industries. We assisted the Board of Peakdale Molecular in exploring strategic opportunities as it became evident that it would need to establish additional scale to take advantage of emerging market opportunities. A sale was agreed to a newly formed Equistone Private Equity backed buy and build entity Concept Life Sciences. Peakdale Molecular formed the central part of a combined $100m deal value providing an attractive exit for existing shareholders.

Proveca focuses on the re-engineering of existing generic medicines to make them appropriate for use by young people. Proveca was a start-up with proven management who were seeking to obtain a Paediatric Marketing Use Authorisation (PUMA) on three drugs. In 2012, we helped them secure a funding package with Albion Ventures. Proveca has now been granted its first PUMA and has several other drug opportunities in the pipeline. Bamburgh Capital retains an equity shareholding.

Concepta plc is a UK- based Women’s Healthcare company which has been founded to help women with unexplained infertility to conceive. In 2014 we helped Concepta secure investment from a combination of high net worth individuals, the Angel Co Investment fund and Enterprise Ventures. In 2016, Concepta listed on AIM and has a current market capitalisation of over £20m. Bamburgh Capital retains an equity shareholding in Concepta.

Back to top